Equities Analysts Issue Forecasts for Oculis Holding AG's Q2 2024 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Stock analysts at HC Wainwright upped their Q2 2024 EPS estimates for shares of Oculis in a research note issued on Wednesday, April 24th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.37) per share for the quarter, up from their previous forecast of ($0.41). HC Wainwright has a "Buy" rating and a $28.00 price target on the stock. The consensus estimate for Oculis' current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for Oculis' Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.35) EPS and FY2024 earnings at ($1.44) EPS.

Other analysts have also issued research reports about the stock. Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Oculis in a report on Tuesday, March 19th. Wedbush reaffirmed an "outperform" rating and set a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Finally, Robert W. Baird cut their target price on Oculis from $64.00 to $35.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 19th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $29.14.

Oculis Price Performance

Shares of OCS traded up $0.07 on Friday, reaching $12.02. 88,399 shares of the company's stock were exchanged, compared to its average volume of 46,649. The business has a 50 day moving average price of $11.86 and a two-hundred day moving average price of $11.23. Oculis has a 12 month low of $9.05 and a 12 month high of $14.50. The company has a current ratio of 5.29, a quick ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. abrdn plc acquired a new position in shares of Oculis in the fourth quarter valued at approximately $15,980,000. Compagnie Lombard Odier SCmA increased its holdings in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock worth $1,053,000 after purchasing an additional 30,750 shares in the last quarter. Searle & CO. acquired a new stake in shares of Oculis in the 4th quarter valued at about $112,000. Wolverine Asset Management LLC acquired a new stake in shares of Oculis in the 3rd quarter valued at about $77,000. Finally, Barclays PLC bought a new stake in shares of Oculis in the second quarter valued at about $44,000. 22.30% of the stock is owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.